{"id":15128,"date":"2026-11-06T14:05:44","date_gmt":"2026-11-06T14:05:44","guid":{"rendered":"https:\/\/wepharm.com\/2026\/11\/06\/primeiro-estudo-clinico-controlado-com-wepaticare-apresentado-no-ecvim-ca-congress-2026\/"},"modified":"2026-11-06T14:11:43","modified_gmt":"2026-11-06T14:11:43","slug":"primeiro-estudo-clinico-controlado-com-wepaticare-apresentado-no-ecvim-ca-congress-2026","status":"publish","type":"post","link":"https:\/\/wepharm.com\/pt-pt\/2026\/11\/06\/primeiro-estudo-clinico-controlado-com-wepaticare-apresentado-no-ecvim-ca-congress-2026\/","title":{"rendered":"Primeiro estudo cl\u00ednico controlado com WePaticare\u00ae apresentado no ECVIM-CA Congress 2026"},"content":{"rendered":"\n<h3 class=\"wp-block-heading\">Um estudo prospetivo e controlado da Faculdade de Medicina Veterin\u00e1ria da Universidade de Lisboa, apresentado no 36th ECVIM-CA Congress (Berlim, 2026), traz a primeira evid\u00eancia cl\u00ednica controlada sobre o WePaticare\u00ae associado ao \u00e1cido ursodesoxic\u00f3lico (UDCA) em c\u00e3es.<\/h3>\n\n<p class=\"wp-block-paragraph\">A hepatite cr\u00f3nica representa cerca de 66% dos casos de hepatite prim\u00e1ria em c\u00e3es, e at\u00e9 20% destes casos s\u00e3o subcl\u00ednicos. Muitas vezes, a \u00fanica pista \u00e9 a eleva\u00e7\u00e3o das enzimas hep\u00e1ticas em an\u00e1lises de rotina. A terap\u00eautica hepatoprotetora \u00e9 usada quase sempre como coadjuvante nestes casos, mas faltava evid\u00eancia cl\u00ednica controlada que a sustentasse.<\/p>\n\n<p class=\"wp-block-paragraph\">Foi essa lacuna que o estudo da FMV-ULisboa, financiado pela Wepharm, procurou preencher.<\/p>\n\n<p class=\"wp-block-paragraph\">A hepatite cr\u00f3nica representa cerca de 66% dos casos de hepatite prim\u00e1ria em c\u00e3es, e at\u00e9 20% destes casos s\u00e3o subcl\u00ednicos. Muitas vezes, a \u00fanica pista \u00e9 a eleva\u00e7\u00e3o das enzimas hep\u00e1ticas em an\u00e1lises de rotina. A terap\u00eautica hepatoprotetora \u00e9 usada quase sempre como coadjuvante nestes casos, mas faltava evid\u00eancia cl\u00ednica controlada que a sustentasse.<\/p>\n\n<p class=\"wp-block-paragraph\">Foi essa lacuna que o estudo da FMV-ULisboa, financiado pela Wepharm, procurou preencher.<\/p>\n\n<h4 class=\"wp-block-heading\">Como foi feito o estudo<\/h4>\n\n<p class=\"wp-block-paragraph\">O estudo decorreu no Hospital Escolar Veterin\u00e1rio da FMV-ULisboa, com recrutamento entre mar\u00e7o e setembro de 2025. Inclu\u00eda c\u00e3es com pelo menos uma enzima hep\u00e1tica elevada (ALT, ALP e\/ou GGT) e suspeita de doen\u00e7a hepatobiliar prim\u00e1ria, sustentada por imagem abdominal.<\/p>\n\n<p class=\"wp-block-paragraph\">Os 30 c\u00e3es foram distribu\u00eddos por dois grupos:<\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>G1:<\/strong> WePaticare\u00ae + UDCA (n = 19)<\/li>\n\n\n\n<li><strong>G2:<\/strong> UDCA isoladamente, como controlo ativo (n = 11)<\/li>\n<\/ul>\n\n<p class=\"wp-block-paragraph\">As an\u00e1lises foram repetidas ao 1.\u00ba e ao 3.\u00ba m\u00eas de tratamento e comparadas com os valores iniciais.<\/p>\n\n<figure class=\"wp-block-gallery has-nested-images columns-default is-cropped wp-block-gallery-1 is-layout-flex wp-block-gallery-is-layout-flex\">\n<figure class=\"wp-block-image size-large\"><img fetchpriority=\"high\" decoding=\"async\" width=\"819\" height=\"1024\" data-id=\"15120\" src=\"https:\/\/wepharm.com\/wp-content\/uploads\/2026\/11\/estudo_wepaticare_post_EN_01-1-819x1024.png\" alt=\"\" class=\"wp-image-15120\" srcset=\"https:\/\/wepharm.com\/wp-content\/uploads\/2026\/11\/estudo_wepaticare_post_EN_01-1-819x1024.png 819w, https:\/\/wepharm.com\/wp-content\/uploads\/2026\/11\/estudo_wepaticare_post_EN_01-1-768x960.png 768w, https:\/\/wepharm.com\/wp-content\/uploads\/2026\/11\/estudo_wepaticare_post_EN_01-1-240x300.png 240w, https:\/\/wepharm.com\/wp-content\/uploads\/2026\/11\/estudo_wepaticare_post_EN_01-1.png 1080w\" sizes=\"(max-width: 819px) 100vw, 819px\" \/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"819\" height=\"1024\" data-id=\"15126\" src=\"https:\/\/wepharm.com\/wp-content\/uploads\/2026\/11\/estudo_wepaticare_post_EN_03-1-819x1024.png\" alt=\"\" class=\"wp-image-15126\" srcset=\"https:\/\/wepharm.com\/wp-content\/uploads\/2026\/11\/estudo_wepaticare_post_EN_03-1-819x1024.png 819w, https:\/\/wepharm.com\/wp-content\/uploads\/2026\/11\/estudo_wepaticare_post_EN_03-1-240x300.png 240w, https:\/\/wepharm.com\/wp-content\/uploads\/2026\/11\/estudo_wepaticare_post_EN_03-1-768x960.png 768w, https:\/\/wepharm.com\/wp-content\/uploads\/2026\/11\/estudo_wepaticare_post_EN_03-1.png 1080w\" sizes=\"(max-width: 819px) 100vw, 819px\" \/><\/figure>\n<\/figure>\n\n<h4 class=\"wp-block-heading\">Principais resultados<\/h4>\n\n<ul class=\"wp-block-list\">\n<li><strong>ALP: 84,2% dos c\u00e3es do grupo combinado melhoraram, contra 36,4% no grupo controlo (p = 0,015).<\/strong><\/li>\n\n\n\n<li>GGT: 78,9% contra 36,4% (p = 0,047).<\/li>\n\n\n\n<li>ALT: redu\u00e7\u00e3o significativa no grupo combinado (p = 0,005), j\u00e1 vis\u00edvel ao 1.\u00ba m\u00eas.<\/li>\n\n\n\n<li>Grupo controlo: nenhum dos seis par\u00e2metros avaliados variou de forma significativa.<\/li>\n\n\n\n<li>Tolerabilidade: sem efeitos adversos no grupo combinado. Com UDCA isolado, cerca de 27% dos c\u00e3es tiveram sinais gastrointestinais ligeiros, revers\u00edveis.<\/li>\n<\/ul>\n\n<h4 class=\"wp-block-heading\"><strong>O que significa para a pr\u00e1tica cl\u00ednica<\/strong><\/h4>\n\n<p class=\"wp-block-paragraph\">Os resultados sugerem que associar WePaticare\u00ae ao UDCA pode refor\u00e7ar a resposta bioqu\u00edmica, sobretudo quando a ALT e a GGT s\u00e3o os marcadores mais alterados. O estudo posiciona o WePaticare\u00ae como coadjuvante do UDCA, e n\u00e3o como alternativa: o UDCA continua a ser a base da terap\u00eautica.<\/p>\n\n<p class=\"wp-block-paragraph\">Os autores colocam a hip\u00f3tese de que a boa toler\u00e2ncia digestiva no grupo combinado se deva \u00e0 formula\u00e7\u00e3o multimodal do WePaticare\u00ae, em particular ao seu componente probi\u00f3tico. \u00c9 uma hip\u00f3tese que estudos futuros ter\u00e3o de confirmar.<\/p>\n\n<figure class=\"wp-block-gallery has-nested-images columns-default is-cropped wp-block-gallery-2 is-layout-flex wp-block-gallery-is-layout-flex\">\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"819\" height=\"1024\" data-id=\"15124\" src=\"https:\/\/wepharm.com\/wp-content\/uploads\/2026\/11\/estudo_wepaticare_post_EN_02-1-819x1024.png\" alt=\"\" class=\"wp-image-15124\" srcset=\"https:\/\/wepharm.com\/wp-content\/uploads\/2026\/11\/estudo_wepaticare_post_EN_02-1-819x1024.png 819w, https:\/\/wepharm.com\/wp-content\/uploads\/2026\/11\/estudo_wepaticare_post_EN_02-1-240x300.png 240w, https:\/\/wepharm.com\/wp-content\/uploads\/2026\/11\/estudo_wepaticare_post_EN_02-1-768x960.png 768w, https:\/\/wepharm.com\/wp-content\/uploads\/2026\/11\/estudo_wepaticare_post_EN_02-1.png 1080w\" sizes=\"(max-width: 819px) 100vw, 819px\" \/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"819\" height=\"1024\" data-id=\"15122\" src=\"https:\/\/wepharm.com\/wp-content\/uploads\/2026\/11\/estudo_wepaticare_post_EN_04-819x1024.png\" alt=\"\" class=\"wp-image-15122\" srcset=\"https:\/\/wepharm.com\/wp-content\/uploads\/2026\/11\/estudo_wepaticare_post_EN_04-819x1024.png 819w, https:\/\/wepharm.com\/wp-content\/uploads\/2026\/11\/estudo_wepaticare_post_EN_04-768x960.png 768w, https:\/\/wepharm.com\/wp-content\/uploads\/2026\/11\/estudo_wepaticare_post_EN_04-240x300.png 240w, https:\/\/wepharm.com\/wp-content\/uploads\/2026\/11\/estudo_wepaticare_post_EN_04.png 1080w\" sizes=\"(max-width: 819px) 100vw, 819px\" \/><\/figure>\n<\/figure>\n\n<h4 class=\"wp-block-heading\"><strong>Sobre o estudo<\/strong><\/h4>\n\n<p class=\"wp-block-paragraph\">Estudo conduzido no Hospital Escolar Veterin\u00e1rio da FMV-ULisboa (CIISA \/ AL4AnimalS), com financiamento da Wepharm, S.A. (conflito de interesse declarado pelos autores). Autores: Rita Yasemin Moniz Ibrahimoglu, Patr\u00edcia Lunet Marques, Ana Isabel Filipe e Rodolfo Oliveira Leal. Apresentado como poster no 36th ECVIM-CA Congress, Berlim, 2026.<\/p>\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/wepharm.com\/pt-pt\/?s=wepaticare&amp;lang=en\" data-type=\"link\" data-id=\"https:\/\/wepharm.com\/pt-pt\/?s=wepaticare&amp;lang=en\">Descubra o WePaticare\u00ae<\/a><\/p>\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Um estudo prospetivo e controlado da Faculdade de Medicina Veterin\u00e1ria da Universidade de Lisboa, apresentado no 36th ECVIM-CA Congress (Berlim, 2026), traz a primeira evid\u00eancia cl\u00ednica controlada sobre o WePaticare\u00ae associado ao \u00e1cido ursodesoxic\u00f3lico (UDCA) em c\u00e3es. A hepatite cr\u00f3nica representa cerca de 66% dos casos de hepatite prim\u00e1ria em c\u00e3es, e at\u00e9 20% destes [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":15131,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[91],"tags":[],"class_list":["post-15128","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-produtos"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>WePaticare\u00ae + UDCA em c\u00e3es: primeiro estudo cl\u00ednico controlado<\/title>\n<meta name=\"description\" content=\"Um estudo da Universidade de Lisboa, apresentado no ECVIM-CA 2026, avalia o WePaticare\u00ae em combina\u00e7\u00e3o com UDCA em 30 c\u00e3es com doen\u00e7a hepatobiliar.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/wepharm.com\/pt-pt\/2026\/11\/06\/primeiro-estudo-clinico-controlado-com-wepaticare-apresentado-no-ecvim-ca-congress-2026\/\" \/>\n<meta property=\"og:locale\" content=\"pt_PT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"WePaticare\u00ae + UDCA em c\u00e3es: primeiro estudo cl\u00ednico controlado\" \/>\n<meta property=\"og:description\" content=\"Um estudo da Universidade de Lisboa, apresentado no ECVIM-CA 2026, avalia o WePaticare\u00ae em combina\u00e7\u00e3o com UDCA em 30 c\u00e3es com doen\u00e7a hepatobiliar.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/wepharm.com\/pt-pt\/2026\/11\/06\/primeiro-estudo-clinico-controlado-com-wepaticare-apresentado-no-ecvim-ca-congress-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Wepharm\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/wepharm\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-06T14:05:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-06T14:11:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/wepharm.com\/wp-content\/uploads\/2026\/11\/estudo_wepaticare_post_EN_01-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"1350\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Marta Frazao\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Marta Frazao\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo estimado de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/wepharm.com\\\/pt-pt\\\/2026\\\/11\\\/06\\\/primeiro-estudo-clinico-controlado-com-wepaticare-apresentado-no-ecvim-ca-congress-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/wepharm.com\\\/pt-pt\\\/2026\\\/11\\\/06\\\/primeiro-estudo-clinico-controlado-com-wepaticare-apresentado-no-ecvim-ca-congress-2026\\\/\"},\"author\":{\"name\":\"Marta Frazao\",\"@id\":\"https:\\\/\\\/wepharm.com\\\/#\\\/schema\\\/person\\\/31a062ae4c15544dc85854b77c556fc3\"},\"headline\":\"Primeiro estudo cl\u00ednico controlado com WePaticare\u00ae apresentado no ECVIM-CA Congress 2026\",\"datePublished\":\"2026-11-06T14:05:44+00:00\",\"dateModified\":\"2026-11-06T14:11:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/wepharm.com\\\/pt-pt\\\/2026\\\/11\\\/06\\\/primeiro-estudo-clinico-controlado-com-wepaticare-apresentado-no-ecvim-ca-congress-2026\\\/\"},\"wordCount\":512,\"publisher\":{\"@id\":\"https:\\\/\\\/wepharm.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/wepharm.com\\\/pt-pt\\\/2026\\\/11\\\/06\\\/primeiro-estudo-clinico-controlado-com-wepaticare-apresentado-no-ecvim-ca-congress-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/wepharm.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/estudo_wepaticare_post_EN_01-1.png\",\"articleSection\":[\"Produtos\"],\"inLanguage\":\"pt-PT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/wepharm.com\\\/pt-pt\\\/2026\\\/11\\\/06\\\/primeiro-estudo-clinico-controlado-com-wepaticare-apresentado-no-ecvim-ca-congress-2026\\\/\",\"url\":\"https:\\\/\\\/wepharm.com\\\/pt-pt\\\/2026\\\/11\\\/06\\\/primeiro-estudo-clinico-controlado-com-wepaticare-apresentado-no-ecvim-ca-congress-2026\\\/\",\"name\":\"WePaticare\u00ae + UDCA em c\u00e3es: primeiro estudo cl\u00ednico controlado\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/wepharm.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/wepharm.com\\\/pt-pt\\\/2026\\\/11\\\/06\\\/primeiro-estudo-clinico-controlado-com-wepaticare-apresentado-no-ecvim-ca-congress-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/wepharm.com\\\/pt-pt\\\/2026\\\/11\\\/06\\\/primeiro-estudo-clinico-controlado-com-wepaticare-apresentado-no-ecvim-ca-congress-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/wepharm.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/estudo_wepaticare_post_EN_01-1.png\",\"datePublished\":\"2026-11-06T14:05:44+00:00\",\"dateModified\":\"2026-11-06T14:11:43+00:00\",\"description\":\"Um estudo da Universidade de Lisboa, apresentado no ECVIM-CA 2026, avalia o WePaticare\u00ae em combina\u00e7\u00e3o com UDCA em 30 c\u00e3es com doen\u00e7a hepatobiliar.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/wepharm.com\\\/pt-pt\\\/2026\\\/11\\\/06\\\/primeiro-estudo-clinico-controlado-com-wepaticare-apresentado-no-ecvim-ca-congress-2026\\\/#breadcrumb\"},\"inLanguage\":\"pt-PT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/wepharm.com\\\/pt-pt\\\/2026\\\/11\\\/06\\\/primeiro-estudo-clinico-controlado-com-wepaticare-apresentado-no-ecvim-ca-congress-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-PT\",\"@id\":\"https:\\\/\\\/wepharm.com\\\/pt-pt\\\/2026\\\/11\\\/06\\\/primeiro-estudo-clinico-controlado-com-wepaticare-apresentado-no-ecvim-ca-congress-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/wepharm.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/estudo_wepaticare_post_EN_01-1.png\",\"contentUrl\":\"https:\\\/\\\/wepharm.com\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/estudo_wepaticare_post_EN_01-1.png\",\"width\":1080,\"height\":1350},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/wepharm.com\\\/pt-pt\\\/2026\\\/11\\\/06\\\/primeiro-estudo-clinico-controlado-com-wepaticare-apresentado-no-ecvim-ca-congress-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/wepharm.com\\\/pt-pt\\\/inicio\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Primeiro estudo cl\u00ednico controlado com WePaticare\u00ae apresentado no ECVIM-CA Congress 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/wepharm.com\\\/#website\",\"url\":\"https:\\\/\\\/wepharm.com\\\/\",\"name\":\"Wepharm\",\"description\":\"Animal Welfare\",\"publisher\":{\"@id\":\"https:\\\/\\\/wepharm.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/wepharm.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-PT\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/wepharm.com\\\/#organization\",\"name\":\"Wepharm\",\"url\":\"https:\\\/\\\/wepharm.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-PT\",\"@id\":\"https:\\\/\\\/wepharm.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/wepharm.com\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/logo-wepharm.png\",\"contentUrl\":\"https:\\\/\\\/wepharm.com\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/logo-wepharm.png\",\"width\":336,\"height\":72,\"caption\":\"Wepharm\"},\"image\":{\"@id\":\"https:\\\/\\\/wepharm.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/wepharm\",\"https:\\\/\\\/www.instagram.com\\\/wepharm.aw\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/wepharm.com\\\/#\\\/schema\\\/person\\\/31a062ae4c15544dc85854b77c556fc3\",\"name\":\"Marta Frazao\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-PT\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9f5353edf5a135e8b2b779139a5f4df5cd83d306866ce930df759bdef288c443?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9f5353edf5a135e8b2b779139a5f4df5cd83d306866ce930df759bdef288c443?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9f5353edf5a135e8b2b779139a5f4df5cd83d306866ce930df759bdef288c443?s=96&d=mm&r=g\",\"caption\":\"Marta Frazao\"},\"url\":\"https:\\\/\\\/wepharm.com\\\/pt-pt\\\/author\\\/marta\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"WePaticare\u00ae + UDCA em c\u00e3es: primeiro estudo cl\u00ednico controlado","description":"Um estudo da Universidade de Lisboa, apresentado no ECVIM-CA 2026, avalia o WePaticare\u00ae em combina\u00e7\u00e3o com UDCA em 30 c\u00e3es com doen\u00e7a hepatobiliar.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/wepharm.com\/pt-pt\/2026\/11\/06\/primeiro-estudo-clinico-controlado-com-wepaticare-apresentado-no-ecvim-ca-congress-2026\/","og_locale":"pt_PT","og_type":"article","og_title":"WePaticare\u00ae + UDCA em c\u00e3es: primeiro estudo cl\u00ednico controlado","og_description":"Um estudo da Universidade de Lisboa, apresentado no ECVIM-CA 2026, avalia o WePaticare\u00ae em combina\u00e7\u00e3o com UDCA em 30 c\u00e3es com doen\u00e7a hepatobiliar.","og_url":"https:\/\/wepharm.com\/pt-pt\/2026\/11\/06\/primeiro-estudo-clinico-controlado-com-wepaticare-apresentado-no-ecvim-ca-congress-2026\/","og_site_name":"Wepharm","article_publisher":"https:\/\/www.facebook.com\/wepharm","article_published_time":"2026-11-06T14:05:44+00:00","article_modified_time":"2026-11-06T14:11:43+00:00","og_image":[{"width":1080,"height":1350,"url":"https:\/\/wepharm.com\/wp-content\/uploads\/2026\/11\/estudo_wepaticare_post_EN_01-1.png","type":"image\/png"}],"author":"Marta Frazao","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Marta Frazao","Tempo estimado de leitura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/wepharm.com\/pt-pt\/2026\/11\/06\/primeiro-estudo-clinico-controlado-com-wepaticare-apresentado-no-ecvim-ca-congress-2026\/#article","isPartOf":{"@id":"https:\/\/wepharm.com\/pt-pt\/2026\/11\/06\/primeiro-estudo-clinico-controlado-com-wepaticare-apresentado-no-ecvim-ca-congress-2026\/"},"author":{"name":"Marta Frazao","@id":"https:\/\/wepharm.com\/#\/schema\/person\/31a062ae4c15544dc85854b77c556fc3"},"headline":"Primeiro estudo cl\u00ednico controlado com WePaticare\u00ae apresentado no ECVIM-CA Congress 2026","datePublished":"2026-11-06T14:05:44+00:00","dateModified":"2026-11-06T14:11:43+00:00","mainEntityOfPage":{"@id":"https:\/\/wepharm.com\/pt-pt\/2026\/11\/06\/primeiro-estudo-clinico-controlado-com-wepaticare-apresentado-no-ecvim-ca-congress-2026\/"},"wordCount":512,"publisher":{"@id":"https:\/\/wepharm.com\/#organization"},"image":{"@id":"https:\/\/wepharm.com\/pt-pt\/2026\/11\/06\/primeiro-estudo-clinico-controlado-com-wepaticare-apresentado-no-ecvim-ca-congress-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/wepharm.com\/wp-content\/uploads\/2026\/11\/estudo_wepaticare_post_EN_01-1.png","articleSection":["Produtos"],"inLanguage":"pt-PT"},{"@type":"WebPage","@id":"https:\/\/wepharm.com\/pt-pt\/2026\/11\/06\/primeiro-estudo-clinico-controlado-com-wepaticare-apresentado-no-ecvim-ca-congress-2026\/","url":"https:\/\/wepharm.com\/pt-pt\/2026\/11\/06\/primeiro-estudo-clinico-controlado-com-wepaticare-apresentado-no-ecvim-ca-congress-2026\/","name":"WePaticare\u00ae + UDCA em c\u00e3es: primeiro estudo cl\u00ednico controlado","isPartOf":{"@id":"https:\/\/wepharm.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/wepharm.com\/pt-pt\/2026\/11\/06\/primeiro-estudo-clinico-controlado-com-wepaticare-apresentado-no-ecvim-ca-congress-2026\/#primaryimage"},"image":{"@id":"https:\/\/wepharm.com\/pt-pt\/2026\/11\/06\/primeiro-estudo-clinico-controlado-com-wepaticare-apresentado-no-ecvim-ca-congress-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/wepharm.com\/wp-content\/uploads\/2026\/11\/estudo_wepaticare_post_EN_01-1.png","datePublished":"2026-11-06T14:05:44+00:00","dateModified":"2026-11-06T14:11:43+00:00","description":"Um estudo da Universidade de Lisboa, apresentado no ECVIM-CA 2026, avalia o WePaticare\u00ae em combina\u00e7\u00e3o com UDCA em 30 c\u00e3es com doen\u00e7a hepatobiliar.","breadcrumb":{"@id":"https:\/\/wepharm.com\/pt-pt\/2026\/11\/06\/primeiro-estudo-clinico-controlado-com-wepaticare-apresentado-no-ecvim-ca-congress-2026\/#breadcrumb"},"inLanguage":"pt-PT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/wepharm.com\/pt-pt\/2026\/11\/06\/primeiro-estudo-clinico-controlado-com-wepaticare-apresentado-no-ecvim-ca-congress-2026\/"]}]},{"@type":"ImageObject","inLanguage":"pt-PT","@id":"https:\/\/wepharm.com\/pt-pt\/2026\/11\/06\/primeiro-estudo-clinico-controlado-com-wepaticare-apresentado-no-ecvim-ca-congress-2026\/#primaryimage","url":"https:\/\/wepharm.com\/wp-content\/uploads\/2026\/11\/estudo_wepaticare_post_EN_01-1.png","contentUrl":"https:\/\/wepharm.com\/wp-content\/uploads\/2026\/11\/estudo_wepaticare_post_EN_01-1.png","width":1080,"height":1350},{"@type":"BreadcrumbList","@id":"https:\/\/wepharm.com\/pt-pt\/2026\/11\/06\/primeiro-estudo-clinico-controlado-com-wepaticare-apresentado-no-ecvim-ca-congress-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/wepharm.com\/pt-pt\/inicio\/"},{"@type":"ListItem","position":2,"name":"Primeiro estudo cl\u00ednico controlado com WePaticare\u00ae apresentado no ECVIM-CA Congress 2026"}]},{"@type":"WebSite","@id":"https:\/\/wepharm.com\/#website","url":"https:\/\/wepharm.com\/","name":"Wepharm","description":"Animal Welfare","publisher":{"@id":"https:\/\/wepharm.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/wepharm.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-PT"},{"@type":"Organization","@id":"https:\/\/wepharm.com\/#organization","name":"Wepharm","url":"https:\/\/wepharm.com\/","logo":{"@type":"ImageObject","inLanguage":"pt-PT","@id":"https:\/\/wepharm.com\/#\/schema\/logo\/image\/","url":"https:\/\/wepharm.com\/wp-content\/uploads\/2023\/08\/logo-wepharm.png","contentUrl":"https:\/\/wepharm.com\/wp-content\/uploads\/2023\/08\/logo-wepharm.png","width":336,"height":72,"caption":"Wepharm"},"image":{"@id":"https:\/\/wepharm.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/wepharm","https:\/\/www.instagram.com\/wepharm.aw\/"]},{"@type":"Person","@id":"https:\/\/wepharm.com\/#\/schema\/person\/31a062ae4c15544dc85854b77c556fc3","name":"Marta Frazao","image":{"@type":"ImageObject","inLanguage":"pt-PT","@id":"https:\/\/secure.gravatar.com\/avatar\/9f5353edf5a135e8b2b779139a5f4df5cd83d306866ce930df759bdef288c443?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9f5353edf5a135e8b2b779139a5f4df5cd83d306866ce930df759bdef288c443?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9f5353edf5a135e8b2b779139a5f4df5cd83d306866ce930df759bdef288c443?s=96&d=mm&r=g","caption":"Marta Frazao"},"url":"https:\/\/wepharm.com\/pt-pt\/author\/marta\/"}]}},"_links":{"self":[{"href":"https:\/\/wepharm.com\/pt-pt\/wp-json\/wp\/v2\/posts\/15128","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wepharm.com\/pt-pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wepharm.com\/pt-pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wepharm.com\/pt-pt\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/wepharm.com\/pt-pt\/wp-json\/wp\/v2\/comments?post=15128"}],"version-history":[{"count":1,"href":"https:\/\/wepharm.com\/pt-pt\/wp-json\/wp\/v2\/posts\/15128\/revisions"}],"predecessor-version":[{"id":15134,"href":"https:\/\/wepharm.com\/pt-pt\/wp-json\/wp\/v2\/posts\/15128\/revisions\/15134"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wepharm.com\/pt-pt\/wp-json\/wp\/v2\/media\/15131"}],"wp:attachment":[{"href":"https:\/\/wepharm.com\/pt-pt\/wp-json\/wp\/v2\/media?parent=15128"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wepharm.com\/pt-pt\/wp-json\/wp\/v2\/categories?post=15128"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wepharm.com\/pt-pt\/wp-json\/wp\/v2\/tags?post=15128"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}